Multiple sclerosis: Updates on pathogenesis and therapy. Report from the 9th MS Symposium of the German Multiple Sclerosis Society;Multiple Sklerose: Updates zu pathogenese und therapie: Bericht vom 9. MS-symposium der deutschen multiplen sklerose gesellschaft

Nervenarzt

Volumn 82, Issue 8, 2011, Pages 1026-1035

  Hohlfeld, R ^a   Toyka, K V ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; MULTIPLE SCLEROSIS; PATHOGENESIS;

ANIMALS; DISEASE MODELS, ANIMAL; GERMANY; HUMANS; MULTIPLE SCLEROSIS; SOCIETIES, MEDICAL;

EID: 80755189432     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-011-3264-0     Document Type: Article

References (47)

1. Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129:1953-1971 (Pubitemid 44289062)
2. Krishnamoorthy G, Wekerle H (2009) EAE: An im-munologist's magic eye. Eur J Immunol 39:2031-2035
3. Bartholomäus I, Kawakami N, Odoardi F et al (2009) Effector Tcell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 462:94-98
4. Bettelli E, Baeten D, Jäger A et al (2006) Myelin oligodendrocyte glycoprotein-specific Tand B cells cooperate to induce a Devic-like disease in mice. J Clin Invest 116:2393-2402 (Pubitemid 44330138)
5. Krishnamoorthy G, Lassmann H, Wekerle H, Holz A (2006) Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmuneTcell/B cell cooperation. J Clin Invest 116:2385-2392 (Pubitemid 44330137)
6. Pöllinger B, Krishnamoorthy G, Berer K et al (2009) Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactivetransgenicTcells recruit endogenous MOG-specific B cells. J Exp Med 206:1303-1316
7. Kerschensteiner M, Gallmeier E, Behrens L et al (1999) Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: a neuroprotective role of inflammation? J Exp Med 189:865-870 (Pubitemid 29189691)
8. Linker RA, Lee DH, Demir S et al (2010) Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis. Brain 133:2248-2263
9. Bittner S, Meuth SG, Gobel K et al (2009) TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain 132:2501-2516
10. Meuth SG, Melzer N, Kleinschnitz C et al (2009) Multiple Sklerose - eine Kanalopathie? Ionenkanä-le und Transporter als pharmakologische Zielstrukturen in der entzündlichen Neurodegeneration. Nervenarzt 80:422-429
11. Kapoor R, Furby J, Hayton T et al (2010) Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 9:681-688
12. Bendszus M, Ladewig G, Jestaedt L et al (2008) Ga-dofluorine M enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a quantitative MRI study. Brain 131:2341-2352
13. Stoll G, Bendszus M (2009) Imaging of inflammation in the peripheral and central nervous system by magnetic resonance imaging. Neuroscience 158:1151-1160
14. Vellinga MM, Oude Engberink RD, Seewann A et al (2008) Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 131:800-807 (Pubitemid 351294725)
15. Ladewig G, Jestaedt L, Misselwitz B et al (2009) Spatial diversity of blood-brain barrier alteration and macrophage invasion in experimental autoimmune encephalomyelitis: a comparative MRI study. Exp Neurol 220:207-211
16. Ascherio A, Munch M (2000) Epstein-Barr virus and multiple sclerosis. Epidemiology 11:220-224 (Pubitemid 30112026)
17. Serafini B, Rosicarelli B, Franciotta D et al (2007) Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204:2899-2912 (Pubitemid 350179559)
18. Sargsyan SA, Shearer AJ, Ritchie AM et al (2010) Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology 74:1127-1135
19. Lunemann JD, Munz C (2009) EBV in MS: guilty by association? Trends Immunol 30:243-248
20. Meinl E, Krumbholz M, Hohlfeld R (2006) Blineage cells in the inflammatory CNS environment: migration, maintenance, local antibody production and therapeutic modulation. Ann Neurol 59:880-892 (Pubitemid 43830920)
21. Obermeier B, Mentele R, Malotka J et al (2008) Matching of oligoclonal Igtranscriptomesand proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 14:688-693 (Pubitemid 351809541)
22. Krumbholz M, Faber H, Steinmeyer F et al (2008) Interferon-β increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131:1455-1463 (Pubitemid 351806460)
23. Brilot F, Dale RC, Selter RC et al (2009) Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 66:833-842
24. Selter RC, Brilot F, Grummel V et al (2010) Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 74:1711-1715
25. Derfuss T, Parikh K, Velhin S et al (2009) Contac-tin-2/Tag-1 directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci U S A 106:8302-8307
26. Mathey EK, Derfuss T, Storch MK et al (2007) Neu-rofascin as a novel target for autoantibody-media-ted axonal injury. J Exp Med 204:2363-2372 (Pubitemid 47529322)
27. Kumpfel T, Hoffmann LA, Pellkofer H et al (2008) Multiple sclerosis and the TNFRSF1A R92Q mutation: clinical characteristics of 21 cases. Neurology 71:1812-1820
28. Kumpfel T, Hohlfeld R (2009) Multiple sclerosis. TNFRSF1 A, TRAPS and multiple sclerosis. Nat Rev Neurology 5:528-529
29. De Jager PL, Jia X, Wang J et al (2009) Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 41:776-782
30. Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridi-ne in multiple sclerosis. Ann Neurol 68:494-502
31. Goodman AD, Cohen JA, Cross A et al (2007) Fam-pridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 13:357-368
32. Husseini L, Leussink VI, Kieseier BC, Hartung HP (2010) 4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis. Nervenarzt 81:203-211
33. Wade DT, Collin C, Stott C, Duncombe P (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16:707-714
34. Zipp F, Aktas O (2006) The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 29:518-527 (Pubitemid 44291819)
35. Siffrin V, Vogt J, Radbruch H et al (2010) Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci 33:202-210
36. Siffrin V, Radbruch H, Glumm R et al (2010) In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 33:424-436
37. Jones JL, Anderson JM, Phuah CL et al (2010) Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 133:2232-2247
38. Aktas O, Kury P, Kieseier B, Hartung HP (2010) Fin-golimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol 6:373-382
39. Moharregh-Khiabani D, Linker RA, Gold R, Stangel M (2009) Fumaric acid and its esters: an emerging treatment for multiple sclerosis. Curr Neuropharmacol 7:60-64
40. Aktas O, Prozorovski T, Smorodchenko A et al (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 173:5794-5800 (Pubitemid 39392169)
41. Cohen JA, Barkhof F, Comi G et al (2010) Oral fin-golimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362:402-415
42. Kappos L, Radue EW, O'Connor P et al (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362:387-401
43. Giovannoni G, Comi G, Cook S et al (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362:416-426
44. Henze T, Rieckmann P, Toyka KV (2006) Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol 56:78-105
45. Rieckmann P (2006) Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006). Nervenarzt 77:1506-1518 (Pubitemid 44950149)
46. Rieckmann P, Toyka KV, Bassetti C et al (2004) Escalating immunotherapy of multiple sclerosis-new aspects and practical application. J Neurol 251:1329-1339
47. Wiendl H, Toyka KV, Rieckmann P et al (2008) Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 255:1449-1463